Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019)
Vericel (VCEL) reported Non-Current Deffered Revenue of $1.9 million for Q2 2019, little changed on a YoY basis from $1.9 million in Q2 2018, and little changed sequentially from $1.9 million in Q1 2019.
Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019) Analysis & Trends
Vericel (VCEL) has 4 years of Non-Current Deffered Revenue data on file, last reported at $1.9 million in Q2 2019.
- For the quarter ending Q2 2019, Non-Current Deffered Revenue changed 0.0% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2019 stood at $1.9 million (changed 0.0% YoY), and the FY2018 full-year result was $1.7 million, down 19.09% from the prior year.
- Non-Current Deffered Revenue steadied at $1.9 million in Q2 2019, from $1.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.1 million in Q4 2017 to a low of $820000.0 in Q2 2016.
- A 4-year average of $1.6 million and a median of $1.7 million in 2016 frame the typical range for Non-Current Deffered Revenue.
- Peak annual rise in Non-Current Deffered Revenue reached 111.11% in 2018, while the deepest fall reached 19.09% in 2018.
- Tracing VCEL's Non-Current Deffered Revenue over 4 years: stood at $1.7 million in 2016, then rose by 22.05% to $2.1 million in 2017, then dropped by 19.09% to $1.7 million in 2018, then grew by 14.05% to $1.9 million in 2019.
- Business Quant data shows VCEL's Non-Current Deffered Revenue at $1.9 million in Q2 2019, $1.9 million in Q1 2019, and $1.7 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 1.90 Mn |
| Mar 31, 2019 | 1.90 Mn |
| Dec 31, 2018 | 1.67 Mn |
| Sep 30, 2018 | 1.81 Mn |
| Jun 30, 2018 | 1.90 Mn |
| Mar 31, 2018 | 1.70 Mn |
| Dec 31, 2017 | 2.06 Mn |
| Sep 30, 2017 | 1.00 Mn |
| Jun 30, 2017 | 900,000.00 |
| Mar 31, 2017 | 1.63 Mn |
| Dec 31, 2016 | 1.69 Mn |
| Sep 30, 2016 | 1.23 Mn |
| Jun 30, 2016 | 820,000.00 |